GSK3A and melanoma: Although initially thought to be a selective MET inhibitor [39], the cell cytoskeleton proteins vinculin and RhoC in melanoma cells and Glycogen synthase kinase 3α/β (GSK3α/β) as a pro-tumorigenic signaling protein relevant in acute myeloid leukemia (AML) and lung cancer cells have been identified as molecular targets of tivantinib as well [40,41,42].